Australian company Technovalia and its partners Chulalongkorn University and BioNet have announced ethics approval for a phase 2 trial of the ChulaCov19 BNA159 mRNA vaccine as a booster dose in adults.
Australian launch for phase 2 trial of new mRNA vaccine
November 21, 2022 Latest NewsAustralian Biotech
Latest Video
New Stories
-
This unique historical oddity says all we need to know about the institution
May 26, 2026 - - Latest News -
New Zealand's Pharmac consulting on new vaccine brands and wider flu access for young children
May 26, 2026 - - Latest News -
New national survey reveals muscle health screening gap in Australian general practice
May 26, 2026 - - Latest News -
Mayne Pharma awarded legal costs as business expansion gains momentum
May 25, 2026 - - Latest News -
The risk to patients of this institution getting too close to the sun
May 25, 2026 - - Latest News -
Pharmacy Guild urges immediate funding for pharmacy to vaccinate in response to outbreak
May 24, 2026 - - Latest News -
AusBiotech launches survey in response to Budget’s 'blind spot' on R&D impact
May 24, 2026 - - Australian Biotech
